Regulation - Adcetris

Filter

Current filters:

Adcetris

Popular Filters

Seattle Genetics files sBLA for Adcetris in relapsed Hodgkin lymphoma and systemic ALCL

19-03-2013

US biotech firm Seattle Genetics (Nasdaq: SGEN) has submitted a supplemental Biologics License Application…

AdcetrisBiotechnologyNorth AmericaOncologyRegulationSeattle Genetics

FDA grants Seattle Genetics' Adcetris orphan rating in MF

27-11-2012

US biotech firm Seattle Genetics (Nasdaq: SGEN) says its Adcetris (brentuximab vedotin) has been granted…

AdcetrisBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

European Commission grants conditional approval for Adcetris

01-11-2012

Millennium, a wholly owned subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502)…

AdcetrisBiotechnologyEuropeMillennium PharmaceuticalsOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

“Black box” warning for Seattle Genetics’ Adcetris

16-01-2012

US biotech Seattle Genetics (Nasdaq: SGEN) saw its shares fall 5.2% to $17.49 on Friday, after the company…

AdcetrisBiotechnologyNorth AmericaOncologyRegulationSeattle Genetics

Back to top